NSPR InspireMD Inc. - Common Stock
$0,88
Cena · Sie 25, 2026
Dane fundamentalne na dzień Sie 14, 2026
Zakres 52 tyg.
$1–$3
13% of range
Ocena Analityków
BUY
9 analysts
Cena Docelowa
$3
+281% upside
P/E (TTM)
-1.2
ROE
-129.3%
Marża Zysku Netto
-543.3%
NSPR Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$0.88
Kapitalizacja Rynkowa
$38M
P/E (TTM)
-1.2
EPS (TTM)
$-0.76
Przychody (TTM)
$9M
Stopa dywidendy
—
ROE
-129.3%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$1 – $3
NSPR Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$9M
2016-12-31
→
2025-12-31
EPS
$-0.76
2022-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-37M
2016-12-31
→
2025-12-31
Marże
-543.3%
2016-12-31
→
2025-12-31
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
NSPR
Mediana porównawcza
P/E (TTM)
-1.2
15.4
P/S (TTM)
4.2
2.8
P/B
0.7
1.6
Price / FCF (Cena / FCF)
-1.0
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
NSPR
Mediana porównawcza
Gross Margin (Marża brutto)
29.5%
31.6%
Operating Margin (Marża Operacyjna)
-552.6%
—
Net Profit Margin (Marża Zysku Netto)
-543.3%
-49.3%
ROA
-84.0%
-54.9%
ROE
-129.3%
-98.0%
ROIC
-90.0%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
NSPR
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
5.7
4.7
Quick Ratio (Wskaźnik Szybkości)
5.3
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
NSPR
Mediana porównawcza
Revenue YoY (Przychody R/R)
28.1%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
20.2%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
29.3%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
NSPR
Mediana porównawcza
NSPR Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
9 analityków
- Mocne kupno 2 22,2%
- Kup 6 66,7%
- Trzymaj 1 11,1%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
3 analityków · 2026-08-23
Mediana
$3.00
Średnia
$3.33
← Poniżej wszystkich celów
$0.88
Niski
$3.00
Wysoki
$4.00
Średni cel
$3.00
+242,8%
Średnia cel
$3.33
+280,9%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.02%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 31 marca 2026 | $-0.16 | $-0.18 | 0.02% |
| 31 grudnia 2025 | $-0.14 | $-0.20 | 0.06% |
| 30 września 2025 | $-0.17 | $-0.20 | 0.03% |
| 30 czerwca 2025 | $-0.26 | $-0.27 | 0.01% |
| 31 marca 2025 | $-0.22 | $-0.20 | -0.02% |
| 31 grudnia 2024 | $-0.19 | $-0.20 | 0.01% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| NSPR | $77M | -2.3 | 28.1% | -543.3% | -129.3% | 29.5% |
| RXST | $430M | -11.0 | -3.9% | -29.0% | -14.0% | 76.6% |
| UTMD | $178M | 16.1 | -5.8% | 29.3% | 9.5% | 57.1% |
| RMTI | $33M | -5.5 | -31.8% | -7.7% | -15.8% | 16.9% |
| TELA | $53M | -1.4 | 15.8% | -48.4% | -501.1% | 67.7% |
| ADVB | $15M | -4.4 | — | — | -159.1% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 18
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $7M | $6M | $5M | $4M | $2M | $4M | $4M | $3M | $2M | $2M | $3M | |
| Cost of Revenue | $6M | $6M | $4M | $4M | $4M | $2M | $3M | $3M | $2M | $2M | $3M | $2M | |
| Gross Profit | $3M | $2M | $2M | $1M | $754.0K | $83.0K | $756.0K | $995.0K | $585.0K | $102.0K | $-296.0K | $784.0K | |
| R&D Expense | $15M | $14M | $8M | $8M | $5M | $2M | $3M | $2M | $1M | $1M | $4M | $9M | |
| SG&A Expense | $21M | $15M | $11M | $8M | $7M | $6M | $5M | $5M | $5M | $5M | $6M | $9M | |
| Operating Expenses | $52M | $35M | $23M | $20M | $15M | $10M | $11M | $9M | $9M | $8M | $14M | $24M | |
| Operating Income | $-50M | $-34M | $-21M | $-19M | $-15M | $-10M | $-10M | $-8M | $-8M | $-8M | $-14M | $-24M | |
| Interest Expense | · | · | · | · | · | · | · | · | $119.0K | $721.0K | $1M | $1M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $2.0K | |
| Other Non-op | $891.0K | $2M | $1M | $250.0K | $-157.0K | $-160.0K | $-200.0K | $-371.0K | · | · | · | $-1M | |
| Pretax Income | $-49M | $-32M | $-20M | $-18M | $-15M | $-11M | $-10M | $-7M | $-8M | $-8M | $-16M | $-25M | |
| Income Tax | $63.0K | $59.0K | $65.0K | $28.0K | $45.0K | $4.0K | $24.0K | · | $27.0K | $1.0K | $4.0K | $12.0K | |
| Net Income | $-49M | $-32M | $-20M | $-18M | $-15M | $-11M | $-10M | $-7M | $-8M | $-8M | $-16M | $-25M | |
| EPS (Basic) | $-0.76 | $-0.76 | $-0.82 | $-2.35 | $-2.03 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.76 | $-0.76 | $-0.82 | $-2.35 | · | · | · | · | · | · | · | · | |
| Shares (Basic) | 64,325,810 | 41,928,360 | 24,268,181 | 7,871,814 | 7,346,022 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 64,325,810 | 41,928,360 | 24,268,181 | 7,871,814 | · | · | · | · | · | · | · | · | |
| EBITDA | $-50M | $-34M | $-21M | $-19M | $-15M | $-10M | $-10M | $-7M | $-8M | $-8M | $-14M | $-23M |
Bilans 25
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $19M | $10M | $5M | $12M | $13M | $6M | $9M | $4M | $8M | $3M | $6M | |
| Short-term Investments | $45M | $16M | $29M | · | · | · | · | · | · | · | · | · | |
| Receivables | $2M | $2M | $2M | $1M | $1M | $476.0K | $823.0K | $716.0K | $643.0K | $356.0K | $405.0K | $635.0K | |
| Inventory | $3M | $3M | $2M | $2M | $1M | $1M | $1M | $1M | $533.0K | $500.0K | $753.0K | $2M | |
| Prepaid Expense | $1M | $1M | $578.0K | $655.0K | $522.0K | $334.0K | $87.0K | $81.0K | $62.0K | $65.0K | $75.0K | $150.0K | |
| Current Assets | $61M | $41M | $44M | $21M | $37M | $15M | $8M | $11M | $5M | $9M | $5M | $9M | |
| PP&E (Net) | $4M | $2M | $1M | $917.0K | $632.0K | $448.0K | $547.0K | $421.0K | $476.0K | $379.0K | $472.0K | $622.0K | |
| PP&E (Gross) | $6M | $5M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Accum. Depreciation | $3M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $957.0K | $875.0K | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | · | $752.0K | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Total Assets | $69M | $47M | $48M | $25M | $40M | $18M | $10M | $12M | $6M | $9M | $6M | $11M | |
| Accounts Payable | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Accrued Liabilities | $2M | $1M | $1M | $554.0K | $632.0K | $886.0K | $604.0K | $903.0K | $976.0K | $425.0K | $552.0K | $993.0K | |
| Current Liabilities | $11M | $8M | $6M | $5M | $4M | $4M | $3M | $3M | $2M | $5M | $7M | $8M | |
| Capital Leases | $2M | $2M | $1M | $1M | $781.0K | $999.0K | $653.0K | · | · | · | · | · | |
| Total Liabilities | $14M | $11M | $8M | $7M | $6M | $6M | $4M | $4M | $3M | $5M | $9M | $14M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $5M | $9M | |
| Total Debt | · | · | · | · | · | · | · | · | · | $3M | $5M | · | |
| Common Stock | $4.0K | $3.0K | $2.0K | $1.0K | $1.0K | · | · | · | · | · | · | $4.0K | |
| Paid-in Capital | $357M | $290M | $261M | $219M | $217M | $180M | $163M | $156M | $143M | $136M | $120M | · | |
| Retained Earnings | $-302M | $-254M | $-222M | $-202M | $-183M | $-168M | $-158M | $-148M | $-140M | $-132M | $-123M | $-107M | |
| Stockholders' Equity | $55M | $36M | $40M | $17M | $34M | $12M | $5M | $9M | $3M | $4M | $-3M | $-3M | |
| Liabilities + Equity | $69M | $47M | $48M | $25M | $40M | $18M | $10M | $12M | $6M | $9M | $6M | $11M | |
| Shares Outstanding | 43,532,281 | 26,611,033 | 21,841,215 | 8,330,918 | 8,296,256 | 3,284,322 | 3,916,134 | 38,400,000 | 1,483,556 | 42,653 | 314,065 | 4,136,852 |
Przepływy pieniężne 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $476M | $280M | $232M | $188M | $161.0K | $151.0K | $158.0K | $152.0K | $153.0K | $142.0K | $152.0K | $263.0K | |
| Stock-based Comp | $12M | $10M | $4M | $2M | $2M | $606.0K | $325.0K | $70.0K | $672.0K | $978.0K | $3M | $4M | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $148.0K | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $406.0K | · | |
| Other Non-cash | · | · | · | · | · | $706.0K | $-253.0K | $-575.0K | $-518.0K | $-154.0K | $641.0K | $1M | |
| Operating Cash Flow | $-35M | $-22M | $-16M | $-16M | $-13M | $-9M | $-10M | $-8M | $-8M | $-7M | $-12M | $-19M | |
| CapEx | $2M | $1M | $381.0K | $473.0K | $344.0K | $88.0K | $284.0K | $67.0K | $258.0K | $49.0K | $16.0K | $133.0K | |
| Investing Cash Flow | $-31M | $13M | $-16M | $8M | $-22M | $-187.0K | $-387.0K | $-44.0K | $-318.0K | · | · | · | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $-2M | $-3M | $-4M | $-1M | |
| Stock Issued | $1M | $1M | · | · | · | · | $6M | $16M | $7M | $14M | $12M | $10M | |
| Net Stock Activity | $1M | $1M | · | · | · | · | $6M | $16M | $7M | $14M | $12M | $10M | |
| Financing Cash Flow | $56M | $18M | $38M | $-140.0K | $35M | $16M | $6M | $13M | $5M | · | · | · | |
| Net Change in Cash | $-10M | $9M | $5M | $-7M | $-641.0K | $7M | $-4M | $6M | $-4M | $4M | $-3M | $-11M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | $6.0K | $13.0K | · | |
| Free Cash Flow | $-37M | $-23M | $-17M | $-16M | $-14M | $-9M | $-10M | $-8M | $-8M | $-8M | $-12M | $-19M | |
| Levered FCF | · | · | · | · | · | · | · | · | $-9M | $-8M | $-13M | $-21M |
Rentowność 8
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.5% | 21.5% | 29.1% | 21.6% | 16.8% | 3.3% | 20.3% | 27.6% | 21.2% | 5.4% | -12.8% | 27.8% | |
| Operating Margin | -552.6% | -478.0% | -340.7% | -361.9% | -327.4% | -417.7% | -263.8% | -211.4% | -298.1% | -403.8% | -627.1% | -840.9% | |
| Net Margin | -543.3% | -456.6% | -321.0% | -357.6% | -331.9% | -424.3% | -269.8% | -201.1% | -305.6% | -446.7% | -674.7% | -890.5% | |
| Pretax Margin | -542.6% | -455.8% | -319.9% | -357.1% | -330.9% | -424.1% | -269.2% | -201.1% | -304.6% | -446.7% | -674.5% | -890.1% | |
| EBITDA Margin | -552.6% | -478.0% | -340.7% | -361.9% | -327.4% | -411.6% | -259.6% | -207.5% | -292.6% | -396.3% | -616.6% | -831.6% | |
| ROA | -84.0% | -67.8% | -55.1% | -57.5% | -51.9% | -76.2% | -90.6% | -78.7% | -108.8% | -112.0% | -200.6% | -141.7% | |
| ROE | -129.3% | -82.7% | -48.1% | -94.2% | -42.3% | -90.0% | -151.2% | -73.5% | -249.2% | -1539.8% | 885.5% | -857.5% | |
| ROIC | -90.0% | -93.0% | -53.7% | -107.7% | -44.0% | -85.4% | -182.8% | · | -302.8% | -113.7% | -607.0% | 850.7% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.7 | 5.3 | 7.3 | 4.2 | 8.5 | 4.1 | 2.5 | 3.9 | 2.1 | 1.8 | 0.7 | 1.1 | |
| Quick Ratio | 5.3 | 4.7 | 6.8 | 1.1 | 3.0 | 3.5 | 2.0 | 3.5 | 1.8 | 1.6 | 0.5 | 0.8 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | 0.7 | -1.8 | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | -0.4 | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -69.2 | -10.6 | -14.0 | -16.8 |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.2 | |
| Inventory Turnover | 2.1 | 2.4 | 2.4 | 2.9 | 2.9 | 1.8 | 2.5 | · | · | · | 2.8 | 1.2 | |
| Receivables Turnover | 4.8 | 4.2 | 4.4 | 4.6 | 5.3 | 3.8 | 4.8 | 5.3 | 5.5 | 5.0 | 4.3 | 2.3 |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 28.1% | 13.0% | 20.0% | 15.0% | 80.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 20.2% | 16.0% | 35.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 29.3% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9M | $7M | $6M | $5M | $4M | $2M | $4M | $4M | $3M | $2M | $2M | $3M | |
| Net Income TTM | $-49M | $-32M | $-20M | $-18M | $-15M | $-11M | $-10M | $-7M | $-8M | $-8M | $-16M | $-25M | |
| Market Cap | $77M | $70M | $61M | $7M | $25M | $251M | $63M | $4.61B | $5.06B | $96.82B | $4.43T | $211.76T | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | $96.81B | $4.43T | · | |
| P/E | -2.3 | -3.5 | -3.4 | -0.4 | · | · | · | · | · | · | · | · | |
| P/S | 8.6 | 10.0 | 9.9 | 1.4 | 5.6 | 101.1 | 17.0 | 1279.9 | 1833.9 | 51118.1 | 1919018.5 | 75144428.9 | |
| P/B | 1.4 | 1.9 | 1.6 | 0.4 | 0.7 | 20.7 | 11.8 | 526.0 | 1856.8 | 23935.2 | -1504729.4 | -75980265.7 | |
| P / Tangible Book | 1.4 | 1.9 | 1.6 | 0.4 | 0.7 | 20.7 | · | · | · | · | · | · | |
| P / Cash Flow | -2.2 | -3.2 | -3.7 | -0.5 | -1.9 | -27.7 | -6.5 | -606.0 | -622.7 | -12917.6 | -382281.2 | -10936731.8 | |
| P / FCF | -2.1 | -3.0 | -3.7 | -0.4 | -1.8 | -27.4 | -6.3 | -600.7 | -603.6 | -12833.7 | -381754.5 | -10862118.5 | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | -12898.1 | -311214.2 | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -12833.1 | -381754.6 | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | 51115.6 | 1919019.4 | · | |
| Earnings Yield | -42.7% | -28.9% | -29.2% | -273.3% | · | · | · | · | · | · | · | · |
Rachunek zysków i strat 15
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | |
| Cost of Revenue | $3M | $3M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $866.0K | $828.0K | $1M | |
| Gross Profit | $-774.0K | $687.0K | $1M | $864.0K | $313.0K | $292.0K | $469.0K | $414.0K | $331.0K | $292.0K | $505.0K | $438.0K | $491.0K | $373.0K | $198.0K | $366.0K | |
| R&D Expense | $4M | $5M | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| SG&A Expense | $4M | $5M | $5M | $6M | $5M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $2M | |
| Operating Expenses | $14M | $15M | $13M | $14M | $13M | $12M | $10M | $9M | $9M | $8M | $6M | $6M | $6M | $5M | $5M | $5M | |
| Operating Income | $-14M | $-14M | $-12M | $-13M | $-13M | $-11M | $-9M | $-8M | $-8M | $-7M | $-6M | $-6M | $-5M | $-4M | $-5M | $-5M | |
| Other Non-op | $121.0K | $289.0K | $386.0K | $343.0K | $-132.0K | $294.0K | $252.0K | $572.0K | $351.0K | $382.0K | $468.0K | $461.0K | $238.0K | $125.0K | $119.0K | $81.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-5M | $-5M | |
| Net Income | $-14M | $-14M | $-12M | $-13M | $-13M | $-11M | $-9M | $-8M | $-8M | $-7M | $-5M | $-5M | $-5M | $-4M | $-5M | $-5M | |
| EPS (Basic) | $-0.17 | $-0.16 | $-0.11 | $-0.17 | $-0.26 | $0.22 | $-0.17 | $-0.16 | $-0.22 | $-0.21 | $0.10 | $-0.15 | $-0.24 | $-0.53 | $-0.61 | $-0.58 | |
| EPS (Diluted) | $-0.17 | $-0.16 | $-0.11 | $-0.17 | $-0.26 | $0.22 | $-0.17 | $-0.16 | $-0.22 | $-0.21 | $0.10 | $-0.15 | $-0.24 | $-0.53 | $-0.60 | $-0.58 | |
| Shares (Basic) | 84,659,943 | 83,801,839 | -110,138,100 | 73,466,501 | 51,003,900 | 49,993,509 | -76,561,954 | 48,369,412 | 35,877,926 | 34,242,976 | -38,884,299 | 33,984,953 | 21,074,187 | 8,093,340 | -15,578,732 | 7,838,506 | |
| Shares (Diluted) | 84,659,943 | 83,801,839 | -110,138,100 | 73,466,501 | 51,003,900 | 49,993,509 | -76,561,954 | 48,369,412 | 35,877,926 | 34,242,976 | -38,884,299 | 33,984,953 | 21,074,187 | 8,093,340 | 54,840 | 7,838,506 | |
| EBITDA | $-14M | $-14M | · | $-13M | $-13M | $-11M | · | $-8M | $-8M | $-7M | · | $-6M | $-5M | $-4M | · | $-5M |
Bilans 20
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $11M | $9M | $63M | $12M | $12M | $19M | $16M | $28M | $9M | $10M | $14M | $12M | $4M | $5M | $4M | |
| Short-term Investments | $15M | $30M | $45M | · | $8M | $14M | $16M | $25M | $19M | $25M | $29M | $29M | $29M | · | · | · | |
| Receivables | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $2M | $1M | $1M | $1M | $1M | $1M | |
| Inventory | $3M | $3M | $3M | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Prepaid Expense | $1M | $1M | $1M | $945.0K | $947.0K | $893.0K | $1M | $1M | $717.0K | $531.0K | $578.0K | $476.0K | $56.0K | $394.0K | $655.0K | $860.0K | |
| Current Assets | $37M | $49M | $61M | $70M | $25M | $32M | $41M | $46M | $52M | $39M | $44M | $47M | $51M | $17M | $21M | $25M | |
| PP&E (Net) | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $1M | $907.0K | $873.0K | $887.0K | $917.0K | $876.0K | |
| PP&E (Gross) | · | · | $6M | · | · | · | $5M | · | · | · | $3M | · | · | · | $3M | · | |
| Accum. Depreciation | · | · | $3M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Total Assets | $45M | $56M | $69M | $78M | $33M | $39M | $47M | $50M | $56M | $42M | $48M | $50M | $54M | $20M | $25M | $28M | |
| Accrued Liabilities | $1M | $1M | $2M | $735.0K | $1M | $821.0K | $1M | $1M | $1M | $1M | $1M | $926.0K | $742.0K | $933.0K | $554.0K | $1M | |
| Current Liabilities | $10M | $9M | $11M | $11M | $9M | $7M | $8M | $7M | $7M | $5M | $6M | $5M | $5M | $4M | $5M | $4M | |
| Capital Leases | $2M | $2M | $2M | $2M | $3M | $2M | $2M | $682.0K | $786.0K | $914.0K | $1M | $1M | $970.0K | $1M | $1M | $1M | |
| Total Liabilities | $13M | $13M | $14M | $14M | $13M | $10M | $11M | $9M | $9M | $7M | $8M | $7M | $7M | $6M | $7M | $6M | |
| Common Stock | $5.0K | $4.0K | $4.0K | $4.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | |
| Paid-in Capital | $362M | $360M | $357M | $355M | $298M | $293M | $290M | $286M | $283M | $264M | $261M | $259M | $258M | $219M | $219M | $219M | |
| Retained Earnings | $-330M | $-316M | $-302M | $-291M | $-278M | $-265M | $-254M | $-244M | $-236M | $-229M | $-222M | $-216M | $-211M | $-206M | $-202M | $-197M | |
| Stockholders' Equity | $32M | $44M | $55M | $64M | $20M | $28M | $36M | $41M | $47M | $35M | $40M | $43M | $47M | $13M | $17M | $22M | |
| Liabilities + Equity | $45M | $56M | $69M | $78M | $33M | $39M | $47M | $50M | $56M | $42M | $48M | $50M | $54M | $20M | $25M | $28M | |
| Shares Outstanding | 46,921,061 | 46,838,963 | 43,532,281 | 41,919,141 | 32,552,888 | 29,752,661 | 26,611,033 | 25,719,632 | 25,196,479 | 23,412,385 | 21,841,215 | 21,400,163 | 21,192,204 | 8,326,648 | 8,330,918 | 8,335,606 |
Przepływy pieniężne 9
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $3M | $4M | $3M | $3M | $2M | $2M | $3M | $3M | $2M | $2M | $930.0K | $289.0K | $368.0K | $657.0K | |
| Operating Cash Flow | $-11M | $-12M | $-9M | $-9M | $-8M | $-9M | $-7M | $-6M | $-4M | $-5M | $-4M | $-4M | $-3M | $-5M | $-3M | $-5M | |
| CapEx | $330.0K | $194.0K | $398.0K | $329.0K | $576.0K | $359.0K | $311.0K | $421.0K | $475.0K | $195.0K | $215.0K | $96.0K | $45.0K | $25.0K | $95.0K | $226.0K | |
| Investing Cash Flow | $15M | $15M | $-45M | $8M | $5M | $2M | $8M | $-6M | $6M | $5M | $-36.0K | $6M | $-27M | $4M | $4M | $3M | |
| Stock Issued | · | · | $-38M | $38M | $190.0K | $506.0K | $965.0K | $-965.0K | $1M | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | · | · | · | $506.0K | · | · | $1M | · | · | · | · | · | · | · | |
| Financing Cash Flow | · | · | $0 | $53M | $2M | $506.0K | $2M | $-965.0K | · | · | $0 | $0 | · | · | $0 | $-103.0K | |
| Net Change in Cash | $4M | $2M | $-54M | $52M | $-874.0K | $-7M | $3M | $-13M | $19M | $-251.0K | $-4M | $2M | $7M | $-404.0K | $698.0K | $-2M | |
| Free Cash Flow | · | $-13M | · | · | · | $-9M | · | · | · | $-5M | · | · | · | $-5M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -43.7% | 20.2% | · | 34.2% | 17.6% | 19.1% | · | 22.9% | 19.0% | 19.3% | · | 28.1% | 29.8% | 30.1% | · | 25.6% | |
| Operating Margin | -815.6% | -411.4% | · | -517.3% | -732.2% | -749.5% | · | -467.5% | -475.0% | -490.7% | · | -362.4% | -322.3% | -353.6% | · | -322.1% | |
| Net Margin | -808.8% | -402.9% | · | -503.7% | -739.6% | -730.3% | · | -435.9% | -454.8% | -465.4% | · | -332.8% | -307.9% | -343.5% | · | -316.5% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -316.5% | |
| EBITDA Margin | -815.6% | -411.4% | · | -517.3% | -732.2% | -749.5% | · | -467.5% | -475.0% | -490.7% | · | -362.4% | -322.3% | -353.6% | · | -322.1% | |
| ROA | -36.7% | -28.8% | · | -19.7% | -29.5% | -27.7% | · | -15.7% | -14.5% | -22.7% | · | -13.3% | -11.8% | -15.4% | · | -12.8% | |
| ROE | -55.4% | -38.0% | · | -24.1% | -39.2% | -35.2% | · | -18.6% | -16.9% | -29.0% | · | -15.9% | -14.0% | -19.7% | · | -15.4% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 5.1 | · | 6.5 | 2.8 | 4.4 | · | 6.4 | 7.4 | 7.9 | · | 10.0 | 10.5 | 3.8 | · | 6.2 | |
| Quick Ratio | 3.3 | 4.7 | · | 6.0 | 2.3 | 3.8 | · | 5.8 | 7.0 | 7.2 | · | 9.4 | 8.7 | 1.3 | · | 1.3 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.9 | 0.9 | · | 0.5 | 0.6 | 0.5 | · | 0.7 | 0.7 | 0.6 | · | 0.7 | 0.7 | 0.6 | · | 0.8 | |
| Receivables Turnover | 1.0 | 1.7 | · | 1.4 | 1.2 | 1.1 | · | 1.4 | 1.3 | 1.2 | · | 1.4 | 1.2 | 1.0 | · | 1.3 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9M | $9M | · | $8M | $7M | $7M | · | $7M | $6M | $6M | · | $6M | $6M | $5M | · | $5M | |
| Net Income TTM | $-54M | $-51M | · | $-45M | $-40M | $-34M | · | $-28M | $-25M | $-22M | · | $-19M | $-18M | $-18M | · | $-18M | |
| Market Cap | $33M | $76M | · | $101M | $74M | $80M | · | $69M | $63M | $55M | · | $70M | $53M | $9M | · | $12M | |
| P/E | -0.9 | -4.4 | · | -3.0 | -2.6 | -3.3 | · | -3.6 | -3.0 | -2.1 | · | -2.2 | -1.3 | · | · | · | |
| P/S | 3.5 | 8.3 | · | 13.2 | 10.8 | 12.1 | · | 10.4 | 9.8 | 9.3 | · | 11.9 | 9.1 | 1.7 | · | 2.4 | |
| P/B | 1.0 | 1.8 | · | 1.6 | 3.7 | 2.8 | · | 1.7 | 1.3 | 1.6 | · | 1.6 | 1.1 | 0.7 | · | 0.6 | |
| P / Tangible Book | 1.0 | 1.8 | · | 1.6 | 3.7 | 2.8 | · | 1.7 | 1.3 | 1.6 | · | 1.6 | 1.1 | 0.7 | · | 0.6 | |
| P / Cash Flow | · | -6.2 | · | · | · | -9.1 | · | · | · | -11.0 | · | · | · | -1.9 | · | · | |
| P / FCF | · | -6.1 | · | · | · | -8.7 | · | · | · | -10.6 | · | · | · | -1.9 | · | · | |
| Earnings Yield | -108.6% | -22.7% | · | -33.6% | -37.9% | -30.1% | · | -27.6% | -32.8% | -47.7% | · | -45.9% | -77.3% | · | · | · |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $9M | $7M | $6M | $5M | $4M |
| Marża Brutto % | 29.5% | 21.5% | 29.1% | 21.6% | 16.8% |
| Marża Operacyjna % | -552.6% | -478.0% | -340.7% | -361.9% | -327.4% |
| Zysk netto | $-49M | $-32M | $-20M | $-18M | $-15M |
| Rozwodniony EPS | $-0.76 | $-0.76 | $-0.82 | $-2.35 | — |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 5.7 | 5.3 | 7.3 | 4.2 | 8.5 |
| Wskaźnik Szybkości | 5.3 | 4.7 | 6.8 | 1.1 | 3.0 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-37M | $-23M | $-17M | $-16M | $-14M |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 38 emitentów · $14.7M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 8 (+5 vs poprzedni kw.) | 3 (-9 vs poprzedni kw.) | 9 (+6 vs poprzedni kw.) | 5 (-5 vs poprzedni kw.) | -1.3M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $2 734 411 | 3 905 743 | 18,65% | Akcje |
| Aberdeen Group plc | $2 589 225 | 3 698 364 | 17,66% | Akcje |
| Nantahala Capital Management, LLC | $2 363 876 | 3 376 484 | 16,12% | Akcje |
| ORBIMED ADVISORS LLC | $2 193 697 | 3 133 405 | 14,96% | Akcje |
| Parkman Healthcare Partners LLC | $1 691 804 | 2 416 518 | 11,54% | Akcje |
| MARSHALL WACE, LLP | $1 302 284 | 1 860 405 | 8,88% | Akcje |
| Soleus Capital Management, L.P. | $732 100 | 1 045 708 | 4,99% | Akcje |
| PURA VIDA INVESTMENTS, LLC | $315 407 | 450 517 | 2,15% | Akcje |
| Affiance Financial, LLC | $175 284 | 250 370 | 1,20% | Akcje |
| Velan Capital Investment Management LP | $103 711 | 148 138 | 0,71% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $78 994 | 112 832 | 0,54% | Akcje |
| Creative Planning | $76 286 | 108 964 | 0,52% | Akcje |
| Schonfeld Strategic Advisors LLC | $69 502 | 99 275 | 0,47% | Akcje |
| XTX Topco Ltd | $34 325 | 49 029 | 0,23% | Akcje |
| Centiva Capital, LP | $30 891 | 44 123 | 0,21% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $26 378 | 37 677 | 0,18% | Akcje |
| Mesirow Financial Investment Management, Inc. | $21 003 | 30 000 | 0,14% | Akcje |
| COURIER CAPITAL LLC | $21 003 | 30 000 | 0,14% | Akcje |
| VESTIA PERSONAL WEALTH ADVISORS | $17 100 | 24 425 | 0,12% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $14 418 | 20 594 | 0,10% | Akcje |
| LPL Financial LLC | $13 037 | 18 621 | 0,09% | Akcje |
| OSAIC HOLDINGS, INC. | $10 919 | 15 600 | 0,07% | Akcje |
| Avestar Capital, LLC | $10 502 | 15 000 | 0,07% | Akcje |
| CITADEL ADVISORS LLC | $9 521 | 13 600 | 0,06% | Opcja kupna |
| Pallas Capital Advisors LLC | $7 701 | 11 000 | 0,05% | Akcje |
| McKinley Carter Wealth Services, Inc. | $7 001 | 10 000 | 0,05% | Akcje |
| AdvisorNet Financial, Inc | $6 149 | 8 783 | 0,04% | Akcje |
| BlackRock, Inc. | $5 714 | 8 161 | 0,04% | Akcje |
| Farther Finance Advisors, LLC | $700 | 1 000 | 0,00% | Akcje |
| SIMPLEX TRADING, LLC | $521 | 745 | 0,00% | Akcje |
| INGALLS & SNYDER LLC | $258 | 368 800 | 0,00% | Akcje |
| HRT FINANCIAL LP | $41 | 59 754 | 0,00% | Akcje |
| Cambridge Investment Research Advisors, Inc. | $14 | 20 166 | 0,00% | Akcje |
| MORGAN STANLEY | $1 | 1 | 0,00% | Akcje |
| UBS Group AG | $1 | 1 | 0,00% | Akcje |
| Caitong International Asset Management Co., Ltd | $1 | 1 | 0,00% | Akcje |
| CITIGROUP INC | $1 | 1 | 0,00% | Akcje |
| ROYAL BANK OF CANADA | $0 | 247 | 0,00% | Akcje |
Insiderzy spółki 26 insiderów · 12 dyrektorzy generalni · 18 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Marvin Slosman | CEO and President | 12 maja 2026 P | 3 556 658 | 1 | 0 | $25 200 |
| James J Barry | President and CEO | 16 grudnia 2019 A | 2 166 382 | 0 | 0 | $0 |
| Alan Milinazzo | President and CEO | 31 stycznia 2016 F | 158 718 | 0 | 0 | $0 |
| Ofir Paz | CHIEF EXECUTIVE OFFICER | 8 kwietnia 2011 A | — | 0 | 0 | $0 |
| Michael A. Lawless | Chief Financial Officer | 14 stycznia 2026 A | 691 695 | 0 | 0 | $0 |
| Craig Shore | CFO and CAO | 7 stycznia 2025 A | 1 112 460 | 0 | 0 | $0 |
| Andrea Tommasoli | Chief Operating Officer | 14 stycznia 2026 A | 954 389 | 0 | 0 | $0 |
| Shane Thomas Gleason | Chief Commercial Officer | 19 maja 2026 S | 1 053 882 | 0 | 24 | $-288 783 |
| Patrick Verta | EVP Clinical/Medical Affairs | 7 stycznia 2025 A | 311 532 | 0 | 0 | $0 |
| Eli Bar | CTO InspireMD Ltd. | 26 stycznia 2015 A | 342 919 | 0 | 0 | $0 |
| Eric L. Olson | VP of Global Sales Operations | 7 listopada 2014 P | 147 163 | 0 | 0 | $0 |
| Robert Ratini | VP Sales Mkting InspireMD Ltd. | 1 czerwca 2012 A | — | 0 | 0 | $0 |
| Paul Stuka | Dyrektor | 27 maja 2026 P | 667 871 | 14 | 0 | $284 057 |
| Scott R. Ward | Dyrektor | 7 maja 2026 P | 237 096 | 2 | 0 | $102 637 |
| Gary S Roubin | Dyrektor | 7 maja 2026 P | 834 478 | 1 | 0 | $106 200 |
| Danny L. Dearen | Dyrektor | 14 stycznia 2026 A | 102 047 | 0 | 0 | $0 |
| Raymond W Cohen | Dyrektor | 14 stycznia 2026 A | 92 417 | 0 | 0 | $0 |
| Michael Berman | Dyrektor | 14 stycznia 2026 A | 352 586 | 0 | 0 | $0 |
| Kathryn Arnold | Dyrektor | 30 grudnia 2025 A | 303 087 | 0 | 0 | $0 |
| Thomas J Kester | Dyrektor | 15 września 2025 A | 458 573 | 0 | 0 | $0 |
| Campbell Rogers | Dyrektor | 13 października 2021 A | 27 960 | 0 | 0 | $0 |
| Sol J Barer | Dyrektor | 7 grudnia 2016 A | 2 942 308 | 0 | 0 | $0 |
| Isaac Blech | Dyrektor | 7 grudnia 2016 A | — | 0 | 0 | $0 |
| James J Loughlin | Dyrektor | 30 czerwca 2015 A | 15 000 | 0 | 0 | $0 |
| Asher Holzer | Dyrektor | 26 listopada 2013 S | 1 925 110 | 0 | 0 | $0 |
| Eyal Weinstein | Dyrektor | 9 maja 2013 A | — | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 7 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Marvin Slosman | 24 kwietnia 2026 | 5,18% | Pierwotne zgłoszenie | — | SEC |
| Michael A. Lawless | 29 października 2025 | 8,60% | Pierwotne zgłoszenie | — | SEC |
| Craig Shore ×2 zgłoszenia | 29 października 2025 | 3,50% | Aneks | — | SEC |
| Sol J. Barer ×3 zgłoszenia | 20 kwietnia 2016 | — | Pierwotne zgłoszenie | — | SEC |
| OFIR PAZ, SARA PAZ ×2 zgłoszenia | 28 stycznia 2014 | — | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Asher Holzer ×2 zgłoszenia | 16 stycznia 2014 | — | Pierwotne zgłoszenie | — | SEC |
| OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., OrbiMed Advisors LLC, OrbiMed Capital GP IV LLC, Samuel D. Isaly | 22 kwietnia 2013 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 1 fundusz ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IWC · iShares Trust | 0,01% | 116 342 SH | 20 sierpnia 2026 | Dziennie |